The serum lipid profile of Parkinson's disease patients: a study from China

References

• Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32 Suppl:S125–7.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197–211.
   PubMed Web of Science ®Google Scholar
• Fantini J, Carlus D, Yahi N. The fusogenic tilted peptide (67–78) of alpha-synuclein is a cholesterol binding domain. Biochim Biophys Acta 2011;1808(10):2343–51.
   PubMed Web of Science ®Google Scholar
• Bar-On P, Crews L, Koob AO, et al. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 2008;105(5):1656–67.
   PubMed Web of Science ®Google Scholar
• Marwarha G, Rhen T, Schommer T, et al. The oxysterol 27-hydroxycholesterol regulates alpha-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors–relevance to Parkinson's disease. J Neurochem 2011;119(5):1119–36.
   PubMed Web of Science ®Google Scholar
• Huang X, Abbott RD, Petrovitch H, et al. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord 2008;23(7):1013–8.
   PubMed Web of Science ®Google Scholar
• Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69(17):1688–95.
   PubMed Web of Science ®Google Scholar
• de Lau LM, Koudstaal PJ, Hofman A, et al. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006;164(10):998–1002.
   PubMed Web of Science ®Google Scholar
• Hu G, Antikainen R, Jousilahti P, et al. Total cholesterol and the risk of Parkinson disease. Neurology 2008;70(21):1972–9.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Tanaka K, Fukushima W, et al. Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010;293(1–2):82–6.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen H, Miller WC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord 2007;22(3):377–81.
   PubMed Web of Science ®Google Scholar
• Savica R, Grossardt BR, Ahlskog JE, et al. Metabolic markers or conditions preceding Parkinson's disease: a case-control study. Mov Disord 2012;27(8):974–9.
   PubMed Web of Science ®Google Scholar
• Cassani E, Cereda E, Barichella M, et al. Cardiometabolic factors and disease duration in patients with Parkinson's disease. Nutrition 2013;29(11–12):1331–5.
   PubMed Web of Science ®Google Scholar
• Huang X, Auinger P, Eberly S, et al. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One 2011;6(8):e22854.
   PubMed Web of Science ®Google Scholar
• Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007;5:20.
   PubMed Web of Science ®Google Scholar
• Gao X, Simon KC, Schwarzschild MA, et al. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012;69(3):380–4.
   PubMed Web of Science ®Google Scholar
• Wahner AD, Bronstein JM, Bordelon YM, et al. Statin use and the risk of Parkinson disease. Neurology 2008;70(16 Pt 2):1418–22.
   PubMed Web of Science ®Google Scholar
• Mutez E, Duhamel A, Defebvre L, et al. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol Res 2009;60(1):41–5.
   PubMed Web of Science ®Google Scholar
• Lee YC, Lin CH, Wu RM, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81(5):410–6.
   PubMed Web of Science ®Google Scholar
• Ritz B, Manthripragada AD, Qian L, et al. Statin use and Parkinson's disease in Denmark. Mov Disord 2010;25(9): 1210–6.
   PubMed Web of Science ®Google Scholar
• Becker C, Jick SS, Meier CR. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf 2008;31(5):399–407.
   PubMed Web of Science ®Google Scholar
• Samii A, Carleton BC, Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J Clin Neurosci 2008;15(11):1272–3.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
   PubMed Web of Science ®Google Scholar
• Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis. Diabetes Care 2011;34(12):2614–23.
   PubMed Web of Science ®Google Scholar
• Scigliano G, Ronchetti G, Girotti F, et al. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 2009;15(2):138–43.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129–70.
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001;57(10 Suppl 3):S11–26.
   PubMed Web of Science ®Google Scholar
• Scigliano G, Musicco M, Soliveri P, et al. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006;37(5):1184–8.
   PubMed Web of Science ®Google Scholar
• Cereda E, Cassani E, Barichella M, et al. Low cardiometabolic risk in Parkinson's disease is independent of nutritional status, body composition and fat distribution. Clin Nutr 2012;31(5):699–704.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Nakamura Y, Kiyozuka T, et al. Serological profiles of urate, paraoxonase-1, ferritin and lipid in Parkinson's disease: changes linked to disease progression. Neurodegener Dis 2011;8(4):252–8.
   PubMed Web of Science ®Google Scholar
• Barichella M, Akpalu A, Cham M, et al. Nutritional status and dietary habits in Parkinson's disease patients in Ghana. Nutrition 2013;29(2):470–3.
   PubMed Web of Science ®Google Scholar
• Aden E, Carlsson M, Poortvliet E, et al. Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study. Nutr Neurosci 2011;14(1):25–31.
   PubMed Web of Science ®Google Scholar
• Kaikkonen J, Nyyssonen K, Tuomainen TP, et al. Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999; 443(2):163–6.
   PubMed Web of Science ®Google Scholar
• Cleren C, Yang L, Lorenzo B, et al. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 2008;104(6):1613–21.
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009;109(5):1427–39.
   PubMed Web of Science ®Google Scholar
• Dexter DT, Jenner P. Parkinson's disease: From pathology to molecular disease mechanisms. Free Radic Biol Med 2013.
   PubMed Web of Science ®Google Scholar
• Cereda E, Cassani E, Barichella M, et al. Anthropometric indices of fat distribution and cardiometabolic risk in Parkinson's disease. Nutr Metab Cardiovasc Dis 2013;23(3):264–71.
   PubMed Web of Science ®Google Scholar